Article ; Online: Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch.
2023 Volume 32, Issue 5, Page(s) 593–602
Abstract: Cerebrovascular accidents (CVAs) or strokes are part of the common thrombotic manifestations of Systemic Lupus Erythematosus (SLEs) and Antiphospholipid syndrome (APS). Such neurological thrombotic events tend to occur in patients with SLE at a higher ... ...
Abstract | Cerebrovascular accidents (CVAs) or strokes are part of the common thrombotic manifestations of Systemic Lupus Erythematosus (SLEs) and Antiphospholipid syndrome (APS). Such neurological thrombotic events tend to occur in patients with SLE at a higher frequency when Antiphospholipid antibodies (aPLs) are present, and tend to involve the large cerebral vessels. The mechanism of stroke in SLE can be driven by complement deposition and neuroinflammation involving the blood-brain barrier although the traditional cardiovascular risk factors remain major contributing factors. Primary prevention with antiplatelet therapy and disease activity controlling agent is the basis of the management. Anticoagulation via warfarin had been a tool for secondary prevention, especially in stroke recurrence, although the debate continues regarding the target international normalized ratio (INR). The presence of either of the three criteria antiphospholipid antibodies (aPLs) and certain non-criteria aPL can be an independent risk factor for stroke. The exact mechanism for the involvement of the large cerebral arteries, especially in lupus anticoagulant (LAC) positive cases, is still to be deciphered. The data on the role of non-criteria aPL remain very limited and heterogenous, but IgA antibodies against β2GPI and the D4/5 subunit as well as aPS/PT IgG might have a contribution. Anticoagulation with warfarin has been recommended although the optimal dosing or the utility of combination with antiplatelet agents is still unknown. Minimal data is available for direct oral anticoagulants (DOACs). |
---|---|
MeSH term(s) | Humans ; Antiphospholipid Syndrome/complications ; Warfarin ; Lupus Erythematosus, Systemic/complications ; Antibodies, Antiphospholipid ; Lupus Coagulation Inhibitor ; Stroke/chemically induced ; Thrombosis/prevention & control ; Anticoagulants/adverse effects |
Chemical Substances | Warfarin (5Q7ZVV76EI) ; Antibodies, Antiphospholipid ; Lupus Coagulation Inhibitor ; Anticoagulants |
Language | English |
Publishing date | 2023-03-20 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 1154407-7 |
ISSN | 1477-0962 ; 0961-2033 |
ISSN (online) | 1477-0962 |
ISSN | 0961-2033 |
DOI | 10.1177/09612033231165151 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3717: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.